Skip to Content

Chimeric Antigen Receptor T-Cell Therapies for Cancer, 1st Edition

Author :
Edited by Daniel W. Lee and Nirali N. Shah
From patient referral to post-therapy management, Chimeric Antigen Receptor (CAR) T-Cell Therapies for Cancer: A Practical Guide presents a comprehensive view of CAR modified T-cells in a concise and practical format. Providing authoritative guidance ...view more

From patient referral to post-therapy management, Chimeric Antigen Receptor (CAR) T-Cell Therapies for Cancer: A Practical Guide presents a comprehensive view of CAR modified T-cells in a concise and practical format. Providing authoritative guidance on the implementation and management of CAR T-cell therapy from Drs. Daniel W. Lee and Nirali N. Shah, this clinical resource keeps you up to date on the latest developments in this rapidly evolving area.

ISBN :
9780323661812
Publication Date :
02-12-2019
Stock Status :
Please allow 10-14 working days for delivery
Earn 11 Points
Earn 10 Points
Add to Cart

From patient referral to post-therapy management, Chimeric Antigen Receptor (CAR) T-Cell Therapies for Cancer: A Practical Guide presents a comprehensive view of CAR modified T-cells in a concise and practical format. Providing authoritative guidance on the implementation and management of CAR T-cell therapy from Drs. Daniel W. Lee and Nirali N. Shah, this clinical resource keeps you up to date on the latest developments in this rapidly evolving area.


Key Features
  • Covers all clinical aspects, including patient referral, toxicities management, comorbidities, bridging therapy, post-CAR monitoring, and multidisciplinary approaches to supportive care.
  • Includes key topics on associated toxicities such as predictive biomarkers, infections, and multidisciplinary approaches to supportive care.
  • Presents current knowledge on FDA approved CAR T-cell products as well as developments on the horizon.
  • Editors and authors represent leading investigators in academia and worldwide pioneers of CAR therapy.

Author Information
Edited by Daniel W. Lee and Nirali N. Shah, Lasker Clinical Research Scholar, Pediatric Oncology Branch, National Cancer Institute, Bethesda, Maryland, United States
More Information
ISBN Number 9780323661812
Description Author List Edited by Daniel W. Lee and Nirali N. Shah, Lasker Clinical Research Scholar, Pediatric Oncology Branch, National Cancer Institute, Bethesda, Maryland, United States
Copyright Year 2020
Edition Number 1
Format Book
Trim 191w x 235h (7.50" x 9.25")
Imprint Elsevier
Page Count 230
Publication Date 2 Dec 2019
Stock Status Please allow 10-14 working days for delivery

eBooks : Built for busy schedules & tailored for your goals.

Affordable knowledge, built for you

Get the resources you need-often at a lower cost than print. Quality content designed to support your goals, without stretching your budget.

Seamless access wherever you are

Open your eBook on your laptop, tablet, or phone - online or offline. Learning fits into your life, no matter where you go.

Always in sync

Start reading on one device and pick up right where you left off on another. Your progress and notes stay with you, every step of the way.

Tools the make learning stick

Highlight key points, take notes, create flashcards, or listen to your eBook read aloud. Interactive features help you deepen your knowledge, your way.

 

Your eBook is ready whenever you are!

1.  Check your email for your access code.

2.  Sign into or create your VitalSource account and redeem your code.

3.  Open your eBook - ready whenever you are!

FAQ

The access code for your new eBook will be sent in your order confirmation email. Your code can also be accessed in your My Account section on the Elsevier webshop. If you do not receive your code within a few minutes, please check your spam folder.


Step-by-step guidance on how to download Bookshelf and also redeem your code can be found here.


The access code for your new eBook does not expire. However, we always suggest redeeming immediately after purchase to start experiencing the benefits of and insights from your purchase. Important to note - the code provided is a single use code and only valid for the edition you purchase. It does not provide access to past nor future editions of the title.


You will have unlimited access to your eBook on the device to which it was downloaded.


Discover the various learning features that our eBooks offer on the Bookshelf® Reader! For example, you can highlight different text passages, create notes and flashcards, have the text read to you, etc. Particularly practical: You can also use your eBooks offline. More information on the learning functions can be found on the Vitalsource page.


Quality is our top priority. That's why we collaborate with the leading eBook reader provider VitalSource. VitalSource has its own eBook reader Bookshelf®, which you can easily download. This reader is very user-friendly and offers more features than other standard readers. For example, you can highlight different text passages, create notes and flashcards, have the text read to you, etc. Particularly practical: You can also use your eBooks offline. More information can be found on the Vitalsource page.


Elsevier offers its eBooks in ePub format, as we believe this format is best suited to display our content ideally on as many devices as possible.


You can return your eBook within 13 days of purchase. eBooks that have been partially printed or flipped through more than 15% are excluded from returns.

Any questions ?

Support Center >

Top Picks from Our Community

Introduction
1. When to Refer a Patient for CAR-T Cell Therapy
2. Optimizing the Apheresis Product
3. CAR T Cells: Cell Processing Laboratory Considerations
4. Peri-CAR-T Cell Management
5. Management of Cytokine Release Syndrome
6. Special Considerations for ICU Management of Patients Receiving CAR Therapy
7. Neurotoxicities After CAR-T Cell Immunotherapy
8. Hematologic and Non-CRS Toxicities
9. Response Assessment and PosteCAR-T Cell Therapy Management
10. Relapse Management and Role for Consolidative Hematopoietic Stem Cell Transplantation Following CAR-T Cell Therapy
11. Promising Chimeric Antigen Receptors for Non-B Cell Hematological Malignancies, Pediatric Solid Tumors, and Carcinomas
12. CAR T Cell Therapy for CNS Malignancies
13. CAR 2.0: The Next Generation of Synthetic ReceptoreBased Cellular Therapy for Cancer

Write Your Own Review
Only registered users can write reviews. Please sign in or create an account